Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure

Study objective: To evaluate the effects of long-term intermittent dobutami ne infusion (IDI) with concomitant administration of low-dose amiodarone in patients with congestive heart failure (CHF) refractory to standard medica l treatment. Design: Prospective, interventional clinical trial. Setting: Inpatient and outpatient heart failure clinic in a university teac hing hospital. Patients and interventions: Twenty-two patients with CHF refractory to stan dard treatment who could be weaned from dobutamine therapy after an initial 72-h infusion were included in this study. The first 11 patients (group 1) were treated with IDI, 10 mug/kg/min, as needed (mean, once every 16 days, lasting for 12 to 48 h); the next 11 patients (group 2) received oral amio darone, 480 mg/d, and IDI, 10 mug/kg/min, for 8 h every 7 days. Measurement and results: There were no differences in baseline clinical, he modynamic, and five biochemical characteristics between the two groups. The left ventricular ejection fraction was 13.5 +/- 4.5% in group 1 vs 15.5 +/ - 4.9% in group 2 (mean +/- SD; p = 0.451); mean pulmonary capillary wedge pressure was 31.3 +/- 4.4 mm Hg vs 29.4 +/- 3.3 mm Hg (p = 0.316); serum cr eatinine was 1.9 +/- 0.4 mg/dL vs 1.6 +/- 0.5 mg/dL (p = 0.19); and serum N a was 139.6 +/- 6.2 mEq/L vs 138.4 +/- 3.1 mEq/L (p = 0.569). At 12 months of follow-up, 1 of 11 patients (9%) was alive in group 1 vs 6 of 11 patient s (55%) in group 2 (p = 0.011). Furthermore, in group 2, the functional sta tus improved significantly within the first 3 months of treatment, from New York Heart Association functional class IV to 2.63 +/- 0.5 (p = 0.0001). Conclusion: Long-term IDI in conjunction,vith amiodarone, added to conventi onal drugs, improved clinical status and survival of patients with severe C HF.